- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 65,790
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphopenia
- Interventions
- nogapendekin-alfa inbakicept
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
- Biological · Procedure · Radiation + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
- Interventions
- Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Houston, Texas • Richmond, Virginia
- Conditions
- Infertility
- Interventions
- Not listed
- Lead sponsor
- Progyny, Inc.
- Industry
- Eligibility
- Up to 43 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • New York, New York
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease, Frontotemporal Lobar Degeneration, Memory Disorders
- Interventions
- Navigated Care
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California • Omaha, Nebraska
- Conditions
- Failure to Thrive
- Interventions
- Somatropin (rDNA origin) for injection
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Copanlisib, Pertuzumab, Trastuzumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma
- Interventions
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Drug
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Functional Constipation, Pelvic Floor Disorders
- Interventions
- Oculus go headset/virtual reality headset, Diaphragmatic breathing
- Device · Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
- Conditions
- Obesity
- Interventions
- CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 15
- States / cities
- Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
- Conditions
- Thyroid Cancer
- Interventions
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure
- Interventions
- Longitudinal Equity Action Plan
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Spasticity With Multiple Sclerosis
- Interventions
- Nabiximols, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
- Conditions
- Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Psychosocial Effects of Cancer and Its Treatment, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- educational intervention, counseling intervention, psychosocial support for caregiver
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myocarditis
- Interventions
- Muromonab-CD3, Cyclosporine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
- Interventions
- Consolidative radiation therapy (cRT)
- Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 39 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
- Conditions
- Stroke
- Interventions
- Transcranial magnetic stimulation (TMS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • La Jolla, California • Sacramento, California + 1 more
- Conditions
- Defect of Articular Cartilage
- Interventions
- Hyalofast, Microfracture
- Device · Procedure
- Lead sponsor
- Anika Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 18
- States / cities
- Tempe, Arizona • Los Angeles, California • San Diego, California + 14 more